As previously reported, Wedbush upgraded CytomX Therapeutics (CTMX) to Outperform from Neutral with an $8 price target. The firm notes CytomX shared initial dose-escalation data for its masked EGFR x CD3 T-cell engager CX-904 program currently in development in a collaboration with Amgen (AMGN). While early, Wedbush believes the data is encouraging, and looks forward to confirmation of the efficacy signal in pancreatic cancer patients, and insight into activity in other tumor types. The firm also notes that CytomX has recently announced entering into a supply agreement and collaboration with Merck (MRK) to assess CX-801 in combination with pembrolizumab in a variety of solid tumors. Wedbush cites additional promising validation of the masking technology for TCEs and progression of the clinical pipeline programs for the upgrade.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTMX:
- CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)
- CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
- CytomX Therapeutics, Merck enter CX-801 trial collaboration
- CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)
- CytomX Therapeutics upgraded to Buy from Hold at Jefferies